Several new systems are been developed to make the diagnosis and treatment of diseases better and offer the patients with a better quality of life. At present, computed tomography is mostly used to detect and map the lung lesions, which offers an imaging resolution adequate to observe them. Usually, during the surgeries and biopsies, fluoroscopes are utilized; however, the low quality of image makes it unfeasible to precisely observe whether the surgeon is excising the accurate margins of the tissue.
Body Vision Medical, a pioneering medical device organization, claims to have overcome this issue with the introduction of a new system, LungVision. Recently, the company also declared about the approval received by them from the US Food and Drug Administration to market its system. The new Lung Vision system comprises the intraoperative 2-dimesional imaging from the fluoroscope, a tracking technology and navigation catheter that superimposes pre-procedural imaging data, and the conduit of the catheter to direct the operator accurately to its target.
LungVision, the primary system founded on the Body Vision platform, illustrated excellent outcomes through the multicenter clinical trials conducted in the United States. With the use of an advanced augmented reality technique, the new system enables the physicians to map, track, and visualize radiolucent lesions and endobronchial tools instantaneously. The synergistic imaging of LungVision integrates the pre-operative high-resolution imaging, for instance, computed tomography, with intraoperative fluoroscopy. Body Vision software, disposable tools, and hardware assist the surgeons to visualize, track, and plan their navigation during these processes.
According to the company, the new system has following benefits:
- Minimally invasive instantaneous lesion navigation and localization;
- Significant decrease in procedure costs and time;
- Flawless incorporation with a wide range of clinical environments and devices.
- Kyle Hogarth, one of the primary users of LungVision in the North America, said, “Body Vision has produced an exclusive technology that integrates the intelligence of mapping with the ease of fluoroscopy. It allows efficient localization and better lung lesion biopsy, advancing the standard techniques utilized in the daily practice.”
The outcomes of the first study in humans of the LungVision will be soon discussed at the American Thoracic Society meeting.